南方医科大学学报

南方医科大学学报 ›› 2006, Vol. 26 ›› Issue (06): 754-756.

• • 上一篇    下一篇

抗感染纳米羟基磷灰石局部药物缓释微球的研制及体外释药实验

王永峰； 靳安民； 魏坤； 王旭东； 汤善华； 闵少雄；   

  1. 南方医科大学珠江医院骨科中心； 华南理工大学材料学院； 南方医科大学珠江医院骨科中心 广东广州510282； 广东广州510282； 广东广州510641；
  • 出版日期:2006-06-20 发布日期:2006-06-20
  • 基金资助:
    国家自然科学基金(50272021);广东省重点攻关项目(A302020205)~~

Development of an anti-infection nano-hydroxypatite drug delivery microsphere and its drug-release in vitro

WANG Yong-feng1, JIN An-min1, WEI Kun2, WANG Xu-dong2, TANG Shan-hua1, MIN Shao-xiong1 1Department of Othopedics, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China; 2Institute of Material Science and Engineering, South China University of Technology, Guangzhou 510641, China   

  1. 南方医科大学珠江医院骨科中心； 华南理工大学材料学院； 南方医科大学珠江医院骨科中心 广东广州510282； 广东广州510282； 广东广州510641；
  • Online:2006-06-20 Published:2006-06-20

PDF

901

摘要： 目的研制抗感染纳米羟基磷灰石(nano-HA)药物缓释微球,为骨髓炎的治疗提供一新型的局部药物缓释系统(DDS)。方法采用nano-HA为载药核心载体,外包裹生物相容性好且可降解的聚羟基丁酸酯-羟基戊酸酯共聚物/聚乙二醇(PHBV/PEG),承载硫酸庆大霉素(GM)制成nano-HA-PHBV/PEG-GM缓释微球,研究其结构及体外释药特性。结果微球具有明显缓释作用,90mgDDS体外释放实验显示第1天释放量为165.2μg/mL,其后下降并以较低水平稳定释放,维持有效释药时间在28d以上。结论抗感染nano-HA药物缓释微球具有良好的体外缓释作用,有广泛的应用前景。 

Abstract: Objective To develop an anti-infection nano-hydroxypatite (nano-HA) microsphere for local drug delivery for treating osteomyelitis. Methods The nano-HA was used as the core carrier to load gentamicin (GM) and coated with poly(-hydroxybutyrate-co-hydroxyvalerate)/polyethylene glycol (PHBV/PEG), which was degradable and biocompatible, to prepare nano-HA-PHBV/PEG-GM microsphere. The surface structure and in vitro drug-release of the microsphere were studied. Results The microsphere had good drug delivery capability. The samples weighing 90 mg each were soaked in PBS and gentamicin release within the first day was 165.2 μg/ml, which maintained a low release rate in the following days. After 28 days, gentamicin release declined to 8.5 μg/ml, which was higher than the minimal inhibitory concentration of gentamicin (2 μg/ml). Conclusion The local drug delivery system has good drug-release performance in vitro and may possess potential value in clinical management of osteomyelitis.

中图分类号: